Voices of Safety International (VOSI)

  Home    Slip
& Fall
Standards
   SCOF
Testing
   Public
Safety
   Public
Health
   Environmental
Issues
   Forensic
Engineers
   Contacts
& Links
   VOSI
Members
 

VOSI - Public Health Standard V50.3A

Click Here for Printable Version

VOSI  Public Health Standard V50.3A

STANDARD TO DELAY VACCINATING NEWBORNS

1.0 SCOPE

1.1 This standard delays vaccinating newborns until the Immunoglobulin E (IgE) in the umbilical cord blood is tested in order to determine whether a newborn has a compromised immune system that warrants delaying vaccination.

2.0 REFERENCED DOCUMENTS

2.1 Bakerman, Seymour, M.D., Ph.D. "A B Cs of Interpretive Laboratory Data", Second Edition ( 7th. Printing); Interpretive Laboratory Data, Inc., P.O. Box 7066, Greenville, N.C., 27835-7066; ISBN 0-945577-00=1; Copyright 1984

2.2 VOSI Research Report 13 V50.3A "Standard to Delay Vaccinating Newborns"

3.0 TERMINOLOGY

3.1 Hyper IgE - IgE in umbilical cord blood is greater than 2.00 units/ml.

Note: Multiply conventional u/ml by 2.4 to obtain international units in mg/liter. (Ref. 2.1)

4.0 SIGNIFICANCE & USE

4.1 Newborns are typically given the Hepatitis B vaccine, since 1991, before leaving the hospital.

4.2 Ref. 2.1 specifies the following age dependent maximum recommended IgE:

Age
Maximum IgE
U/ml
Newborn 2
1 - 11 months 56
1 year 83
2 years 133
3 years 101
4 years 144
5 years 148
6 years 573

4.3 Less adverse reactions to vaccines will occur when the immune system is strong enough to withstand the stress of vaccination.

4.4 Ref. 2.1 states the following "causes of elevation of serum IgE": parasitic infestations, allergic disorder, immunological disorders of uncertain pathogenesis, and neoplasm.

4.5. Based on the total of 1623 umbilical cord samples, Ref. 2 verifies the accuracy of the 2 U/ml established for maximum IgE.

4.6 The American Academy of Pediatrics (AAP), FDA, CDC and all other groups that recommend vaccines should reference this standard in their regulations and recommendations in accordance with the National Technology Transfer & Advancement Act of 1995 (NTTAA) and the United States National Standards Strategy which requires enforcement by the National Institute of Standards & Technology (NIST). VOSI is one of the 210 "Private Sector Standards Organizations" recognized by NIST (see www.voicesofsafety.com ...."About VOSI").

5.0 KEYWORDS

5.1 Hyper IgE, Immunoglobulin E, Immune System

This STANDARD  was jointly developed by VOSI/Childscreen (www.childscreen.org) under the jurisdiction of Voices of Safety International (VOSI) committee V50 on "Public Health", and subcommittee V50.3 on "Screening Prior to Vaccination" (see www.voicesofsafety.com).

Copies are available FREE on-line at www.voicesofsafety.com . . . Public Health, or from VOSI, 264 Park Ave., N. Caldwell, NJ 07006. 
Ph (973) 228-2258, Fax (973) 228-0276

Voices of Safety International (VOSI) - 1998 - 2017
Contact: webmaster@voicesofsafety.com
Created: 2002-11-18 Last Updated: 2007-02-14